Physician profile
Maria L Sonnack
NPI 1518366913
$99,536.41
in general payments reported to CMS, 2019-2025
20 companies · $30K in 2025
The $30K reported for 2025 was more than what 99% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $12.25 · 2022: $184 · 2023: $21K · 2024: $49K · 2025: $30K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $39K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $23K · Travel and Lodging: $18K · Honoraria: $11K · Food and Beverage: $7,952.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $38,750.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $23,225.75 |
| Travel and Lodging | $18,037.06 |
| Honoraria | $11,375.00 |
| Food and Beverage | $7,952.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $68,864.56 | 2022-2025 | Auvelity, Sunosi |
| Otsuka America Pharmaceutical, INC. | $26,422.19 | 2022-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Supernus Pharmaceuticals, INC. | $883.25 | 2022-2025 | Qelbree, Qelbree |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $875.33 | 2023-2025 | Caplyta |
| Brainsway USA INC | $858.58 | 2025 | Deep Tms System |
| Abbvie INC. | $536.15 | 2021-2025 | |
| Lundbeck LLC | $283.37 | 2024-2025 | Rexulti |
| Corium, LLC | $266.78 | 2022-2025 | Azstarys |
| Idorsia Pharmaceuticals US INC | $119.89 | 2023-2025 | Quviviq, Quviviq |
| Ironshore Pharmaceuticals INC. | $104.02 | 2022-2024 | Jornay Pm |
| Janssen Pharmaceuticals, INC | $65.84 | 2025 | Spravato |
| Takeda Pharmaceuticals U.S.A., INC. | $64.53 | 2023-2024 | Trintellix |
| Tris Pharma INC | $57.18 | 2024-2025 | Dyanavel Xr |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $33.80 | 2024 | Rexulti |
| Exact Sciences Corporation | $21.04 | 2024 | Cologuard Collection Kit |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $18.50 | 2025 | Austedo Xr |
| Neurocrine Biosciences, INC. | $16.66 | 2025 | |
| Collegium Pharmaceutical, INC. | $15.57 | 2025 | Jornay Pm |
| Alkermes, INC. | $14.95 | 2023 | Aristada, Lybalvi |
| Pfizer INC. | $14.22 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maria Sonnack listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.